Citius Pharmaceuticals, Inc. CTXRW 深 滬
已收盤 08-08 16:00:00 美东时间
0.1441
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.1441
- 總市值 1941.04万
- 52周最高 1.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.012
- 委 比 0.00%
- 總股本 1.35亿
- 歷史最高 2.89
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.012
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On May 4, 2026, Cit...
05-09 06:05
Citius Expands LYMPHIR Access with First European Shipment
Citius Pharmaceuticals ( ($CTXR) ) has shared an update. On April 29, 2026, Cit...
04-30 06:33
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international mark...
04-29 20:00
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.
04-24 22:47
Citius Pharmaceuticals to raise $5M in equity offering
Citius Pharmaceuticals (CTXR) said it entered a definitive agreement to sell about 5.08M shares of common stock, or pre-funded warrants, at $0.985 per share in a registered direct offering priced at t...
04-24 20:20
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares moved upwards by 145.6%...
04-24 20:05
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
Citius Pharmaceuticals ( ($CTXR) ) has issued an announcement. On April 6, 2026...
04-07 05:15
Citius Oncology Provides Commercial Update On U.S. Launch Of LYMPHIR For Treatment Of CTCL, Highlighting Continued Adoption And Advancing Investigator-Led Clinical Studies
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integrationCRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius
03-31 21:14
Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CT...
02-24 21:00
